ライフサイエンスコーパス: polyoma virus

1 ex vivo cytolytic activity and clearance of polyoma virus.

2 y conserved region of the large T antigen of polyoma virus.

3 nation inhibition antibodies to the human BK polyoma virus.

4 and usually fatal CNS infection caused by JC polyoma virus.

5 l responses in mice persistently infected by polyoma virus.

6 ding sites were found on middle T antigen of polyoma virus.

7 rstanding the replication cycle of oncogenic polyoma viruses.

8 Polyoma virus, a highly oncogenic natural mouse DNA viru

9 acute and persistent phases of infection by polyoma virus, a mouse pathogen that is capable of poten

10 In mice infected by polyoma virus, a natural mouse pathogen that establishes

11 g infection and preventing tumors induced by polyoma virus, a natural murine papovavirus.

12 l CD8(+) T cells in mice acutely infected by polyoma virus, a persistent mouse pathogen, specifically

13 lation for long-term control of infection by polyoma virus, a persistent mouse pathogen.

14 nation inhibition antibodies to the human JC polyoma virus and from 369 Amerinds from 13 tribes for h

15 he frequencies of precursor CTL specific for polyoma virus and MT(389-397) peptide were similar, indi

16 Because the course of polyoma virus-associated nephropathy (PVAN) has not been

17 on procedure has been devised and applied to polyoma virus based on this rationale.

18 control infection with the B-cell-dependent polyoma virus, because plasma cells were markedly absent

19 Identification of risk factors for BK polyoma virus (BKPyV) without confounding by donor facto

20 Reactivation of BK polyoma virus can result in destructive viral allograft

21 Importantly, CD94/NKG2A(+) anti-polyoma virus CD8 T cells appear to be essential for Ag-

22 racting (p53-TAg) or noninteracting (p53 and polyoma virus coat protein) pairs of proteins, treatment

23 This virus, termed cynomolgus polyoma virus (CPV), is antigenically and genomically re

24 two other alternative reading frames of the polyoma virus early region.

25 TL to recognize cells infected with a mutant polyoma virus encoding a MT truncated just proximal to t

26 The polyoma virus enhancer (PyE) is capable of conferring in

27 otein-2, CCAAT/enhancer-binding protein, and polyoma virus enhancer-3.

28 and origin-binding domains of papilloma and polyoma viruses evolved from a common ancestral protein

29 on, a mouse model was developed using murine polyoma virus expressing a defined CD4(+) T-cell epitope

30 antigen (PyST), an early gene product of the polyoma virus, has been shown to cause cell death in a n

31 Although papilloma and polyoma viruses have differences in capsid size (approxi

32 Patients who had polyoma virus inclusions in renal allograft biopsies wer

33 as a therapeutic option in the management of polyoma virus induced graft failure.

34 d case of successful retransplantation after polyoma virus-induced renal allograft loss.

35 neonates having opposite susceptibilities to polyoma virus-induced tumors.

36 L/6 mice, a mouse strain highly resistant to polyoma virus-induced tumors.

37 IA-1: median, 7%; range, 2-15%) were seen in polyoma virus-infected allografts compared with 24% (ran

38 ) H-2k mice that specifically lyse syngeneic polyoma virus-infected cells and polyoma tumor cells.

39 Polyoma virus-infected MyD88 knockout mice generated str

40 characterize the lymphocytic infiltrates in polyoma virus-infected renal allografts.

41 The median time of diagnosis of polyoma virus infection after transplantation was 9.5 mo

42 In summary, persistent polyoma virus infection both quantitatively and qualitat

43 Polyoma virus infection causes acute interstitial nephri

44 Asymptomatic polyoma virus infection documented by urine cytology or

45 One animal had diarrhea and polyoma virus infection in the smooth muscle cells of th

46 Although polyoma virus infection is being increasingly recognized

47 Polyoma virus infection is characterized by lymphocytic

48 Previous graft loss secondary to polyoma virus infection is not a contraindication to ret

49 the B cells (CD20) in renal allografts with polyoma virus infection of 21% (range, 5-40%) compared w

50 The lymphocytic infiltrates of six cases of polyoma virus infection were compared with six cases of

51 pression predisposes cynomolgus monkeys to a polyoma virus infection with clinical consequences quite

52 Late in polyoma virus infection, early-strand mRNA levels are do

53 ersible graft failure is more prevalent with polyoma virus infection.

54 and enumerate MT389-397-specific CTL during polyoma virus infection.

55 ograft survival was seen in patients who had polyoma virus infection.

56 c T cells in allografts is characteristic of polyoma virus infection.

57 There were 10 cases of polyoma virus infections in renal transplant recipients.

58 ific CD8(+) T cells following infection with polyoma virus, influenza virus, and Listeria monocytogen

59 54 to evaluate a rise in creatinine revealed polyoma virus interstitial nephritis.

60 The BK polyoma virus is a leading cause of chronic post kidney

61 Polyoma virus is a potent oncogenic pathogen when inocul

62 The natural mouse pathogen polyoma virus is highly oncogenic in H-2k mice carrying

63 ain significant antibody titers to the human polyoma viruses JC and BK but do not appear to contain e

64 e in control of viral pathogens including JC polyoma virus (JCV) infection.

65 hat some cases may be associated with the JC polyoma virus (JCV), which is also known to be latent in

66 bition antibody titers against the JC and BK polyoma viruses (JCV and BKV, respectively) are signific

67 Importantly, infection with a polyoma virus lacking MT389-397 and mutated in an MT236-

68 identified as a binding partner of the mouse polyoma virus large T antigen and later shown to possess

69 Persistent anemia, polyoma virus-like nephritis (n = 2), and urinary calciu

70 The calcium bridge between the pentamers of polyoma viruses maintains capsid metastability.

71 er, which is associated with the Merkel cell polyoma virus (MCPyV).

72 Merkel cell polyoma virus (MCV) has been implicated in a majority of

73 Recently, a newly described polyoma virus, Merkel cell polyomavirus (MCPyV), was fou

74 on into the mouse mammary tumor virus (MMTV)-polyoma virus middle T (PyV-mT) transgenic model.

75 mors in the mouse mammary tumor virus (MMTV)-polyoma virus middle T (PyVT) genetic model is delayed b

76 gene knockout and mouse mammary tumor virus-polyoma virus middle T antigen (MMTV-PyMT)-induced breas

77 growth factor receptors and proteins such as polyoma virus middle T antigen (MT).

78 titors in in vitro binding experiments using polyoma virus middle T antigen (MT).

79 itive cells (differentiated astrocytes) with polyoma virus middle T antigen (MTA).

80 (TK-/-) were crossed to mice expressing the polyoma virus middle T antigen (pMT) under the control o

81 Viruses encoding mouse polyoma virus middle T antigen (PyMT) induced tumors, wh

82 V-A-based RCAS vectors encoding either mouse polyoma virus middle T antigen (PyMT) or c-Myc to elasta

83 ed with the mouse mammary tumor virus (MMTV)-Polyoma virus middle T antigen (PyMT) or MMTV-c-Neu tran

84 (MMTV) promoter-driven Ptn expressed in MMTV-polyoma virus middle T antigen (PyMT)-Ptn mouse breast c

85 erived from transgenic mice that express the polyoma virus middle T antigen (PyV-MT) in the mammary g

86 ssion using transgenic mice that express the polyoma virus middle T antigen (PyV-MT) in the mammary g

87 Polyoma virus middle T antigen (PyVmT) is a powerful vir

88 e G11 PLAP transgene was introduced into the polyoma virus middle T antigen mammary tumor model.

89 nse, we engineered mouse mammary tumor virus-polyoma virus middle T antigen mice with endothelial cel

90 ery of avian retroviruses encoding the mouse polyoma virus middle T antigen to elastase-tv-a transgen

91 after the somatic introduction of the mouse polyoma virus middle T antigen to mice with liver-specif

92 c PET and diffusion-weighted (DW)-MRI in the polyoma virus middle T antigen transgenic mouse model of

93 kt levels in total mouse mammary tumor virus-polyoma virus middle T antigen tumor lysates, suggesting

94 Transgenic expression of the polyoma virus middle T antigen, under control of the mou

95 which activates the erythropoietin receptor; polyoma virus middle T antigen, which resembles an activ

96 in transgenic mice expressing the oncogene, polyoma virus middle T antigen.

97 limits mammary tumor initiation in the MMTV-polyoma virus middle T genetic model.

98 background of the mouse mammary tumor virus/polyoma virus middle T oncogene (MMTV-PyMT) mammary canc

99 metastases [mouse mammary tumor virus-driven polyoma virus middle T oncogene (MMTV-PyVT)].

100 were either crossed with mice expressing the polyoma virus middle T oncogene specifically in the mamm

101 mammary tumors due to the expression of the polyoma virus middle T oncogene.

102 nase signaling is the principle mechanism of polyoma virus middle T oncoprotein activation of c-fos e

103 oic acid inhibits transformation of cells by polyoma virus middle T oncoprotein.

104 of Src family kinases to membrane-associated polyoma virus middle T-antigen (PyMT) can result in the

105 l, we crossed MT1-MMP-deficient mice to MMTV-polyoma virus middle T-antigen (PyMT) mice.

106 We have isolated spontaneous mutants of polyoma virus middle T-antigen (PyMT) that do not activa

107 nd3, isolated from mice transformed with the Polyoma virus middle T-antigen is available commercially

108 Although polyoma virus middle T-driven tumors showed altered prim

109 of the late-appearing mammary tumors of MMTV-polyoma virus middle T;Nedd9(-/-) mice are characterized

110 hways that are influenced by IRS-1 using the polyoma virus middle-T (PyV-MT) transgenic mouse model o

111 Murine polyoma virus (MPyV) is a small DNA virus that induces t

112 In comparison to a case-matched polyoma virus-negative control group, the PVN patients w

113 The clinical course of patients with polyoma virus nephritis (PVN) is not well understood, pa

114 (n=7), T-cell-mediated rejection (n=4), and polyoma virus nephropathy (n=1).

115 ade in an attempt to reduce the incidence of polyoma virus nephropathy (PVAN).

116 Polyoma virus nephropathy after transplantation is belie

117 ivity and 57 days for patients who developed polyoma virus nephropathy.

118 me viremic and three patients (1%) developed polyoma virus nephropathy.

119 in a subset of renal allograft kidneys with polyoma virus nephropathy.

120 This effect did not occur with wild-type polyoma virus or RBCs expressing HEL alone.

121 Capsids of papilloma and polyoma viruses (papovavirus family) are composed of 72

122 This highly focused CTL response to polyoma virus provides a valuable animal model to invest

123 Polyoma virus (PV) can cause interstitial nephritis and

124 Polyoma virus (Py) and simian virus 40 (SV40) travel fro

125 Polyoma virus (Py) differs from other small DNA tumor vi

126 In this study polyoma virus (Py) is used as a tool to better define th

127 Using mouse polyoma virus (PyV) as a model of low-level persistent v

128 cells transferred to SCID mice responded to polyoma virus (PyV) infection with T cell-independent (T

129 Using the mouse polyoma virus (PyV) persistent infection model, we recen

130 ighly susceptible to tumors induced by mouse polyoma virus (PyV), but CD8-deficient mice are resistan

131 Using mouse polyoma virus (PyV), we asked whether CD4(+) T cell help

132 Using mouse polyoma virus (PyV), we found that MHC class Ia-deficien

133 The polyoma virus region expressed early in the lytic cycle

134 Leflunomide inhibits Polyoma virus replication in vitro and closely monitored

135 Transformation of cells in culture by polyoma virus requires integration of signals downstream

136 DNA extracted from affected kidneys detected polyoma virus sequences using primers for a highly conse

137 approach is used to explain the structure of polyoma virus, Simian Virus 40 and L-A virus capsids, wh

138 During the persistent phase of infection, polyoma virus-specific CD8 T cells that express CD94/NKG

139 ion is associated with Ag-specific recall of polyoma virus-specific CD8 T cells.

140 ) T-cell help for generating and maintaining polyoma virus-specific CD8(+) T cells.

141 CD4(+) T-cell help for the H-2(b)-restricted polyoma virus-specific CD8(+) T-cell response during acu

142 ly identified the immunodominant epitope for polyoma virus-specific CTL as the Dk-associated peptide

143 ly identified the immunodominant epitope for polyoma virus-specific CTL in tumor-resistant H-2k mice

144 d in an MT236-244 Dk anchor position induced polyoma virus-specific CTL recognizing neither MT389-397

145 The simian polyoma virus SV40 has been detected in specific human t

146 lations with no known exposure to the simian polyoma virus SV40, also were tested for antibodies to t

147 e a manifestation of the activity of a human polyoma virus termed "JC." Among a total of 1,835 person

148 JC virus (JCV) is a polyoma virus that commonly infects humans.

149 g stimulated by the middle T-antigen (MT) of polyoma virus to address this question.

150 Polyoma virus tubulo-interstitial nephritis-associated g

151 xic effector function in mice susceptible to polyoma virus tumorigenesis.

152 Polyoma virus type BK (BKV) nephritis has emerged as an

153 In the present study, a hitherto unknown polyoma virus was detected in 12 of 57 cynomolgus monkey

154 e formation of long-term humoral immunity to polyoma virus was intrinsic to B cells and was independe

155 are highly susceptible to tumor induction by polyoma virus, whereas C57BR/cdj (BR) mice are highly re

156 Infection with a mutant polyoma virus whose MT is truncated just before the MT38